He, Juan Yi, Min Tan, Lingfeng Huang, Jianghua Huang, Lin
Published in
World Journal of Surgical Oncology
BackgroundThe programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown positive efficacy in several solid cancers due to their targeted antitumour effects. However, the frequency and clinical implication value in prostate cancer still remain unclear.MethodsThe PD-1/PD-L1 expression was detected by immunohistochemical (IHC) analysis in...
Hamed, Marwa M Handoussa, Heba Hussein, Nada H Eissa, Reda A Abdel-Aal, Lobna K El Tayebi, Hend M
Published in
Life sciences
Oleuropein, the main secoiridoid glucoside found in Olea europaea L., has attracted scientific community as a potential anticancer agent. Immunotherapy and RNA interference revolutionized cancer treatment. Success of PD-L1/PD-1 antibodies encouraged the investigation of PD-1/PD-L1 regulation by non-coding RNAs. This study aimed to verify the cytoto...
Sun, Yang Tan, Jin Miao, Yuyang Zhang, Qiang
Published in
Cell Communication and Signaling
Hypoxia is a pathological condition common to many diseases, although multiple organ injuries induced by hypoxia are often overlooked. There is increasing evidence to suggest that the hypoxic environment may activate innate immune cells and suppress adaptive immunity, further stimulating inflammation and inhibiting immunosurveillance. We found that...
Farrag, Mayada Saad Abdelwahab, Khaled Farrag, Nesrine Saad Elrefaie, Waleed Elsayed Emarah, Ziad
Published in
Journal of the Egyptian National Cancer Institute
BackgroundP D-L1 is expressed in tumor cells and plays a crucial role in tumor immune escape. Tumor-infiltrating lymphocytes (TILs) as CD8 T cells contribute to reduced tumor growth. Few studies investigated the prognostic effect of PD-L1 and CD8 TILs in ovarian high-grade serous carcinoma (HGSC). In the present study, we analyzed the expression of...
Que, Yi Wang, Juan Zhu, Jia Li, Na Huang, Junting Lu, Suying Sun, Feifei Zhang, Lian Zhen, Zijun Zhang, Li
...
Published in
Frontiers in Immunology
There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in two Chinese expert centers. The primary objective of...
Wang, Song Chen, Shiming Ying, Yufan Ma, Xueyou Shen, Haixiang Li, Jiangfeng Wang, Xiao Lin, Yiwei Liu, Ben Zheng, Xiangyi
...
Published in
Frontiers in Cell and Developmental Biology
Clear cell renal cell carcinoma (ccRCC) is one of the tumor types with sensitivity to ferroptosis, and immunotherapy has emerged as a standard pillar for metastatic ccRCC treatment, while it remains largely obscure whether ferroptosis influences the tumor immune microenvironment in ccRCC. Based on available data in The Cancer Genome Atlas, divergen...
Kubo, Terufumi Shinkawa, Tomoyo Kikuchi, Yasuhiro Murata, Kenji Kanaseki, Takayuki Tsukahara, Tomohide Hirohashi, Yoshihiko Torigoe, Toshihiko
Published in
Frontiers in Oncology
Extensive research over 100 years has demonstrated that tumors can be eliminated by the autologous immune system. Without doubt, immunotherapy is now a standard treatment along with surgery, chemotherapy, and radiotherapy; however, the field of cancer immunotherapy is continuing to develop. The current challenges for the use of immunotherapy are to...
Liang, Chun-Ling Jiang, Hongliang Feng, Wenxuan Liu, Huazhen Han, Ling Chen, Yuchao Zhang, Qunfang Zheng, Fang Lu, Chuan-Jian Dai, Zhenhua
...
Published in
Frontiers in Immunology
Macrophages, a major subset of innate immune cells, are main infiltrating cells in the kidney in lupus nephritis. Macrophages with different phenotypes exert diverse or even opposite effects on the development of lupus nephritis. Substantial evidence has shown that macrophage M2 polarization is beneficial to individuals with chronic kidney disease....
Zou, Jiahuan Xia, Hongwei Zhang, Chenliang Xu, Huanji Tang, Qiulin Zhu, Gongmin Li, Jielang Bi, Feng
Published in
Cancer science
Immunotherapy targeting the PD-L1/PD-1 pathway is a novel type of clinical cancer treatment, but only small subsets of patients can benefit from it because of multiple factors. PD-L1/PD-1 expression is a biomarker for predicting the efficacy of anti-PD-L1/PD-1 therapy, which highlights the importance of understanding the regulatory mechanisms of PD...
Saliba, Maelle Shaheen, Muhammad Hajj, Rana El Abbas, Fatmeh Bashir, Shaarif Sheikh, Umer Nisar Mahfouz, Rami Loya, Asif Khalifeh, Ibrahim
Published in
Cancer immunology, immunotherapy : CII
Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. Tumoral immune microenvironment characterization is essential for considering immune checkpoint inhibitors as a treatment option. A total of 173 resected SCs were reviewed. Clinical information, lesion size, and location were colle...
